TY - JOUR A2 - Ciotti, Marco AU - Abo-amer, Yousry Esam-Eldin AU - Badawi, Rehab AU - El-Abgeegy, Mohamed AU - Elsergany, Heba Fadl AU - Mohamed, Ahmed Abdelhaleem AU - Mostafa, Sahar Mohamed AU - Alegaily, Hatem Samir AU - Soliman, Shaimaa AU - Elnawasany, Sally AU - Abd-Elsalam, Sherief PY - 2020 DA - 2020/07/24 TI - Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure SP - 9075905 VL - 2020 AB - Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination regimens. The primary aim of the study was to assess the efficacy and safety of a quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV DAAs-experienced patients. Methods. This observational, open-label prospective study was carried out on 103 genotype 4 hepatitis C virus-infected patients who failed to achieve SVR12 after sofosbuvir-daclatasvir with or without ribavirin. Patients were treated for three months with sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weight-based ribavirin dosage (1000–1200 mg/d). Response to treatment was determined by quantitative PCR for HCV at 3 months after the end of treatment (SVR12), and adverse events during the treatment were recorded. Results. SVR was achieved in 100 patients (97.1%) at week 12 after treatment. No dangerous or life-threatening adverse events were recorded. Conclusions. Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects. SN - 1687-8639 UR - https://doi.org/10.1155/2020/9075905 DO - 10.1155/2020/9075905 JF - Advances in Virology PB - Hindawi KW - ER -